• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

趋化因子家族:从过敏到HIV感染的潜在治疗靶点

The chemokine family. Potential therapeutic targets from allergy to HIV infection.

作者信息

Proudfoot A E

机构信息

Serono Pharmaceutical Research Institute, 14, chemin des Aulx, 1228 Plan-les-Ouates, CH Genève.

出版信息

Eur J Dermatol. 1998 Apr-May;8(3):147-57.

PMID:9649701
Abstract

Basal trafficking and homing of leukocytes is controlled by a large subfamily of cytokines, the chemokines. The initiation and perpetuation of an inflammatory response is also mediated by the chemokines. The chemokine family acts through a sub-family of the seven transmembrane, G-protein-coupled receptor class. Despite the large number of chemokine proteins, several factors such as regulated expression of the ligands and their receptors, glycosoaminoglycan interactions and their signaling mechanisms introduce the required selectivity in vivo. Recently, chemokine receptors have been identified as an essential component for the infection of host cells by HIV. Chemokine receptors thus present an attractive therapeutic target for inflammatory disorders and HIV infection, and evidence for their validation using antibodies and receptor antagonists is discussed.

摘要

白细胞的基础运输和归巢由一大类细胞因子即趋化因子控制。炎症反应的启动和持续也由趋化因子介导。趋化因子家族通过七跨膜G蛋白偶联受体亚家族发挥作用。尽管趋化因子蛋白数量众多,但诸如配体及其受体的调控表达、糖胺聚糖相互作用及其信号传导机制等多种因素在体内引入了所需的选择性。最近,趋化因子受体已被确定为HIV感染宿主细胞的重要组成部分。因此,趋化因子受体是炎症性疾病和HIV感染有吸引力的治疗靶点,并讨论了使用抗体和受体拮抗剂对其进行验证的证据。

相似文献

1
The chemokine family. Potential therapeutic targets from allergy to HIV infection.趋化因子家族:从过敏到HIV感染的潜在治疗靶点
Eur J Dermatol. 1998 Apr-May;8(3):147-57.
2
Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics.HIV感染中的趋化因子与趋化因子受体:在发病机制及治疗中的作用
J Postgrad Med. 2006 Jul-Sep;52(3):210-7.
3
[The roles of cytokine receptors in diseases].[细胞因子受体在疾病中的作用]
Rinsho Byori. 2000 May;48(5):409-15.
4
Receptor dimerization: a key step in chemokine signaling.受体二聚化:趋化因子信号传导中的关键步骤。
Cell Mol Biol (Noisy-le-grand). 2001 Jun;47(4):575-82.
5
Chemokine blockers--therapeutics in the making?趋化因子阻滞剂——正在研发的治疗药物?
Trends Pharmacol Sci. 2006 Jan;27(1):41-7. doi: 10.1016/j.tips.2005.11.001. Epub 2005 Nov 28.
6
Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins.趋化因子-受体相互作用:G蛋白偶联受体、糖胺聚糖与病毒趋化因子结合蛋白
Adv Protein Chem. 2004;68:351-91. doi: 10.1016/S0065-3233(04)68010-7.
7
Chemokine sequestration by atypical chemokine receptors.非典型趋化因子受体对趋化因子的隔离作用
Biochem Soc Trans. 2006 Dec;34(Pt 6):1009-13. doi: 10.1042/BST0341009.
8
Professional and part-time chemokine decoys in the resolution of inflammation.专业和兼职趋化因子诱饵在炎症消退中的作用
Sci STKE. 2007 May 1;2007(384):pe18. doi: 10.1126/stke.3842007pe18.
9
The expression and function of chemokines involved in CNS inflammation.参与中枢神经系统炎症的趋化因子的表达与功能。
Trends Pharmacol Sci. 2006 Jan;27(1):48-55. doi: 10.1016/j.tips.2005.11.002. Epub 2005 Nov 28.
10
Chemokine receptors: attractive targets for drug discovery.趋化因子受体:药物研发的诱人靶点。
Ann N Y Acad Sci. 2005 Jun;1051:647-57. doi: 10.1196/annals.1361.109.

引用本文的文献

1
Chemical modification of a variant of human MIP-1alpha; implications for dimer structure.人MIP-1α变体的化学修饰;对二聚体结构的影响
Protein Sci. 2000 Oct;9(10):2047-53. doi: 10.1110/ps.9.10.2047.
2
Effects of the neuropeptides substance P, calcitonin gene-related peptide and alpha-melanocyte-stimulating hormone on the IL-8/IL-8 receptor system in a cultured human keratinocyte cell line and dermal fibroblasts.
Inflammation. 1999 Dec;23(6):557-67. doi: 10.1023/a:1020294507767.
3
Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity.细胞毒性对于CD8(+) T细胞介导的接触性超敏反应是必不可少的。
J Exp Med. 1999 Mar 1;189(5):779-86. doi: 10.1084/jem.189.5.779.